Wang CP, et al. – In this study involving a cohort of men with type 2 diabetes (T2D) but not chronic liver diseases (CLD), researchers evaluated the disparities in hepatocellular carcinoma (HCC) incidence across different racial and ethnic groups. They also investigated the impact of metformin use on the disparity. Study participants included men aged 40-89 years with T2D but free from CLD, cancer, and previous cardiovascular or renal diseases who were insulin and thiazolidinedione naïve. The investigators noted that a lower HCC incidence was reported for non-Hispanic African American compared with non-Hispanic white (NHW) or Hispanic men with T2D but without CLD or metformin use; NHW and Hispanic men demonstrated similar HCC incidence. HCC risk was attenuated by metformin use. The race/ethnicity disparity was also modified by metformin use.